Veracyte, Inc. (VCYT)
NASDAQ: VCYT · IEX Real-Time Price · USD
21.26
-0.07 (-0.33%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Veracyte Employees
Veracyte had 815 employees as of December 31, 2023. The number of employees increased by 28 or 3.56% compared to the previous year.
Employees
815
Change (1Y)
28
Growth (1Y)
3.56%
Revenue / Employee
$460,703
Profits / Employee
-$83,653
Market Cap
1.63B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 815 | 28 | 3.56% |
Dec 31, 2022 | 787 | 26 | 3.42% |
Dec 31, 2021 | 761 | 441 | 137.81% |
Dec 31, 2020 | 320 | -34 | -9.60% |
Dec 31, 2019 | 354 | 84 | 31.11% |
Dec 31, 2018 | 270 | 24 | 9.76% |
Dec 31, 2017 | 246 | 30 | 13.89% |
Dec 31, 2016 | 216 | 24 | 12.50% |
Dec 31, 2015 | 192 | 25 | 14.97% |
Dec 31, 2014 | 167 | 52 | 45.22% |
Dec 31, 2013 | 115 | 16 | 16.16% |
Dec 31, 2012 | 99 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
National HealthCare | 13,123 |
Teladoc Health | 5,600 |
Evotec SE | 4,952 |
Galapagos NV | 1,123 |
Immunocore Holdings | 497 |
Mirum Pharmaceuticals | 264 |
Kura Oncology | 142 |
Keros Therapeutics | 136 |
VCYT News
- 4 weeks ago - Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors - Business Wire
- 5 weeks ago - Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer - Business Wire
- 6 weeks ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Veracyte Announces First Quarter 2024 Financial Results - Business Wire
- 2 months ago - 14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding - Business Wire
- 2 months ago - Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 - Business Wire
- 2 months ago - New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance - Business Wire
- 2 months ago - Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 - Business Wire